Gregory B. Russell, M.S.
Director of Statistical Consulting
Senior Biostatistician
Department of Public Health Sciences
Section on Biostatistics
Wake Forest University School of Medicine
Medical Center Blvd.
Winston-Salem, NC 27157
Tel: (336) 716-5449
Fax: (336)716-6427
Email: grussell@wfubmc.edu
Curriculum Vitae
Education:
University of North Carolina - MS, Biostatistics
North Carolina State University – BS, Statistics
Research Topics:
psychological effects of disease
cancer research
cancer prevention
Current Research:
Greg Russell, MS, helps oversee the Design and Analysis Unit, a joint venture between the Department of Biostatistical Sciences and the Office of Research. Mr. Russell is a biostatistician, with expertise in survival analyses and health-related quality of life modeling. His primary focus of interest is the psychological effects of disease; additionally, he works extensively with survival data in modeling risk factors for recurrence and overall survival of cancer patients. In his time outside the Cancer Center, in addition to his work in the Design and Analysis Unit, he is working with the Department of Nephrology on a number of hemo- and peritoneal dialysis projects and the University of Minnesota on a diabetic nephropathy project. Previously, Mr. Russell has been the biostatistician on a large number of projects, including looking at the survivorship of cancer patients after invasive surgery and chemotherapy, as well as looking at the differences in stroke rates within the continental United States and the potential causes for differences in such rates, and prognostic factors in node-negative breast cancer patients.
Selected Recent Publications:
Peacock TP, Shihabi ZK, Bleyer AJ, Dolbare EL, Byers JR, Knovich MA, Calles-Escandon J, Russell GB, Freedman, BI. Comparison of glycated albumin and hemoglobin A1c levels in diabetic subjects on hemodialysis. Kidney Int. 2008 March 73(9): 1062-1068. Epub 2008 Feb 20.
Bleyer AJ, Sedor JR, Freedman BI, O'Brien A, Russell GB, Graley J, Schelling JR. Risk factors for development and progression of diabetic kidney disease and treatment patterns among diabetic siblings of patients with diabetic kidney disease. Am J Kidney Dis. 2008 Jan;51(1):29-37.
Moossavi S, Tuttle AB, Vachharajani TJ, Plonk G, Bettmann MA, Majekodunmi O, Russell GB, Regan JD, Freedman BI. Long-term outcomes of transposed basilic vein arteriovenous fistulae. Hemodial Int. 2008 Jan;12(1):80-4.
McQuellon RP, Russell GB, Shen P, Stewart JH 4th, Saunders W, Levine EA. Survival and health outcomes after cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of appendiceal origin. Ann Surg Oncol. 2008 Jan;15(1):125-33. Epub 2007 Nov 20.
Winter JL, Stackhouse BL, Russell GB, Kute TE. Measurement of PTEN expression using tissue microarrays to determine a race-specific prognostic marker in breast cancer. Arch Pathol Lab Med. 2007 May; 131 (5): 767-72.
Levine EA, Stewart JH 4th, Russell GB, Geisinger KR, Loggie BL, Shen P. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: experience with 501 procedures. J Am Coll Surg. 2007 May;204(5):943-53; discussion 953-5.
Bleyer AJ, Hartman J, Brannon PC, Reeves-Daniel A, Satko SG, Russell G. Characteristics of sudden death in hemodialysis patients. Kidney Int. 2006 Jun;69(12):2268-73. Epub 2006 May 3.
McQuellon RP, Danhauer SC, Russell GB, Shen P, Fenstermaker J, Stewart JH, Levine EA. Monitoring health outcomes following cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol. 2007 Mar;14(3):1105-13. Epub 2007 Jan 6.
Wentworth S, Russell GB, Tuner II, Levine EA, Mishra G, Waters GS, Blackstock AW. Long-term results of local excision with and without chemoradiation for adenocarcinoma of the rectum. Clin Colorectal Cancer. 2005 Jan;4(5):332-5.
Turner II, Russell GB, Blackstock AW, Levine EA. Impact of neoadjuvant therapy on postoperative complications in patients undergoing resection for rectal adenocarcinoma. Am Surg. 2004 Dec;70(12):1045-9.
Huang C, Kim Y, Caramori ML, Fish AJ, Rich SS, Miller ME, Russell GB, Mauer M. Cellular basis of diabetic nephropathy: III. In vitro GLUT1 mRNA expression and risk of diabetic nephropathy in type 1 diabetic patients. Diabetologia. 2004 Oct;47(10):1789-94. Epub 2004 Oct 22.
Kute TE, Russell GB, Zbieranski N, Long R, Johnston S, Williams H, Stackhouse C, Wilkins L, Evans I, Berry P, Rimmer K, Tucker E. Prognostic markers in node-negative breast cancer: a prospective study. Cytometry B Clin Cytom. 2004 May;59(1):24-31.
Inman JL, Russell GB, Savage P, Levine EA. Low-dose adjuvant interferon for stage III malignant melanoma. Am Surg. 2003 Feb;69(2):127-30.
McQuellon RP, Loggie BW, Lehman AB, Russell GB, Fleming RA, Shen P, Levine EA. Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol. 2003 Mar;10(2):155-62.
Huang C, Kim Y, Caramori ML, Fish AJ, Rich SS, Miller ME, Russell GB, Mauer M. Cellular basis of diabetic nephropathy: II. The transforming growth factor-beta system and diabetic nephropathy lesions in type 1 diabetes. Diabetes. 2002 Dec;51(12):3577-81.
Edwards MS, Russell GB, Edwards AF, Hammon JW Jr, Cordell AR, Kon ND. Results of valve replacement with Omniscience mechanical prostheses. Ann Thorac Surg. 2002 Sep;74(3):665-70.
Rinkus KM, Russell GB, Levine EA. Prognostic significance of nodal disease following preoperative radiation for rectal adenocarcinoma. Am Surg. 2002 May;68(5):482-7.
Goff DC Jr, Labarthe DR, Howard G, Russell GB. Primary prevention of high blood cholesterol concentrations in the United States. Arch Intern Med. 2002 Apr 22;162(8):913-9.
McQuellon RP, Moose DB, Russell GB, Case LD, Greven K, Stevens M, Shaw EG. Supportive use of megestrol acetate (Megace) with head/neck and lung cancer patients receiving radiation therapy. Int J Radiat Oncol Biol Phys. 2002 Apr 1;52(5):1180-5.
Fleming RA, Drees J, Loggie BW, Russell GB, Geisinger KR, Morris RT, Sachs D, McQuellon RP. Clinical significance of a NAD(P)H: quinone oxidoreductase 1 polymorphism in patients with disseminated peritoneal cancer receiving intraperitoneal hyperthermic chemotherapy with mitomycin C. Pharmacogenetics. 2002 Jan;12(1):31-7.